Researchers reported spatial predictors that delineate response to chemo-immunotherapy in microsatellite stable (MSS) metastatic colorectal cancer. The study’s core claim is that mapping features within the tumor’s spatial context can help identify which MSS patients are more likely to benefit from treatment approaches that have historically underperformed in this subgroup. The work targets a key clinical problem—MSS mCRC’s limited response rates to immunotherapy—by using spatial information to guide interpretation of therapeutic sensitivity. The report positions the findings as a potential stepping stone toward more individualized patient selection. If validated in additional cohorts, spatial biomarker strategies could reduce the trial-and-error burden in MSS mCRC and refine companion diagnostic development around tumor microenvironment structure.